ema semaglutide expands probe of possible suicide risk to popular weight loss, diabetes drugs EMA flags rare vision risk

What is already known on this topic Glucagon-like peptide-1 (GLP-1) is involved in the development of impaired gallbladder motility Liraglutide, an important member of the GLP-1 receptor agonist class, has been reported to be associated with an increased risk of gallbladder or biliary diseases Glucose dependent insulinotropic polypeptide has also been reported to affect gallbladder motility What this study adds Dipeptidyl peptidase-4 (DPP-4) inhibitors were significantly associated with an increased risk of the composite of gallbladder or biliary diseases and cholecystitis DPP-4 inhibitors were not associated with increased risk of cholelithiasis and biliary diseases Risk of cholecystitis was increased with DPP-4 inhibitors compared with sodium-glucose cotransporter-2 inhibitors but not GLP-1 receptor agonists Ethics statements Ethical approval Not needed

BPC-157 does not have approval for any medical use in the United States, which means it has not met FDA standards for safety, effectiveness, and quality

One study reported up to 40%, while another has found it to be around 10% of the weight lost

Unlike most amino acids, taurine doesnt play a role in building proteins

We're here to answer questions, adjust your treatment as needed, and celebrate your progress throughout your entire weight loss journey